Pharmaceutical companies increasingly outsource their pre-clinical research and development to external structures. This outsourcing to public laboratories or service providers represents a potential market and therefore a real opportunity for economic development. The field of research concerns inflammation, both neuro-inflammation and pulmonary or gastrointestinal inflammation. Severe inflammatory diseases such as asthma or chronic obstructive pulmonary bronchitis are constantly increasing. Inflammatory cytokines are at the heart of these pathologies. Pharmaceutical companies have been looking for the development of cytokine inhibitors for decades, but only biomedicines, such as antibodies, have actually proven their effectiveness to date. Whole swathes are still to be discovered. One of the strengths of the laboratory is its expertise in both inflammatory and infectious pathologies, and a dual competence in immunology but also in neurobiology that allows a cross-analysis of the involvement of new regulatory pathways in these two areas. The complex mechanisms involved require characterisation in animal models. [...]